[Functions and Indications]
To clear scourge and remove toxin, diffuse the lung and discharge heat. Used in the patterns of heat toxin assailing the lung in influenza, manifested as fever or high fever, aversion to cold, muscular soreness, stuffy and runny nose, cough, headache, dry and sore throat, reddish tongue, yellow or yellow and greasy tongue coating. Also indicated for the symptoms of fever, cough, and fatigue caused by the mild and moderate coronavirus disease 2019 (COVID-19) in combination with standard of care.

[Main Ingredients]
Forsythiae Fructus, Lonicerae Japonicae Flos, Ephedrae Herba (processed with honey), Armeniacae Semen Amarum (stir-baked), Gypsum Fibrosum, Isatidis Radix, Dryopteridis Crassirhizomatis Rhizoma, Houttuyniae Herba, Pogostemonis Herba, Rhei Radix et Rhizoma, Rhodiolae Crenulatae Radix et Rhizoma, l-Menthol, Glycyrrhizae Radix et Rhizoma.

[Administration and Dosage]
For oral administration, 4 capsules once, 3 times a day. The course of treatment is 7-10 days for patients with mild and moderate COVID-19.

[Specification] 0.35g /capsule

[Packaging] Aluminum plastic plate packaging, 24 capsules / box, 400 boxes / case

[Approval No.] Z20040063

● Listed in National Essential Drug List
● National Class- A Varieties for Medical Insurance Drugs
● National Key New Product
● Second Prize of National Science and Technology Progress Awards
● “12th-Five Year Plan” Special Project of National Major New Drug Development
● High-tech Demonstration Project of National Development and Reform Commission
● FDA Phase-II Clinical Study

In 2020, Diagnosis and Treatment Scheme for Novel Coronavirus Pneumonia, jointly issued by the Chinese Health Protection Committee and the State Administration of Traditional Chinese Medicine
● In 2019, Diagnosis and Treatment Scheme for Influenza (2019), issued by the National Health Commission
● In 2018, Diagnosis and Treatment Scheme for Influenza (2018), issued by the National Health and Family Planning Commission
● In 2017, Diagnosis and Treatment Scheme for Patients Infected with H7N9 Avian Influenza (Version 1)(2017) , issued by the National Health and Family Planning Commission
● In 2015, Diagnosis and Treatment Scheme for Cases Infected with Middle East Respiratory Syndrome (MERS) (2015), issued by the National Health and Family Planning Commission
● In 2014, Diagnosis and Treatment Scheme for Patients Infected with H7N9 Avian Influenza (2014), issued by the National Health and Family Planning Commission
● In 2013, Expert Consensus on Medical Treatment for Patients Infected with H7N9 Avian Influenza (2013), issued by the National Health and Family Planning Commission
● In 2012, Prevention and Treatment Scheme of Traditional Chinese Medicine for Type B Influenza, issued by the State Administration of Traditional Chinese Medicine
● In 2011, Diagnosis and Treatment Guide for Influenza (2011), issued by the Ministry of Health
● In 2010, Diagnosis and Treatment Scheme for Wind-warm Lung-heat Disease (Non-severe Community Acquired Pneumonia) (2010), issued by the Chinese Health Protection Committee and the State Administration of Traditional Chinese Medicine
● In 2009, Diagnosis and Treatment Scheme for Patients Infected with Type A H1N1 Influenza (2009), issued by the State Administration of traditional Chinese medicine ”
● In 2008, Diagnosis and Treatment Scheme for Patients Infected with Avian Influenza (2008), issued by the Ministry of Health
● In 2005, Diagnosis and Treatment Scheme for Patients Infected with Avian Influenza (2005), issued by the Ministry of Health